Sino Biopharmaceutical (SEHK:1177) has attracted fresh attention after announcing Phase I data for Kylo-11 that cut Lp(a) levels for up to 48 weeks, alongside NMPA approval to begin obesity trial work with TQF6422.
These clinical headlines arrive alongside a mixed share price picture for Sino Biopharmaceutical. The stock closed at HK$5.59 after a 1-day share price return of 6.27%, adding to a 30-day share price return of 13.04% and a 90-day share price return of 19.96%. However, the year-to-date share price return is down 12.11% and the 1-year total shareholder return has declined 31.73%, while the 3-year total shareholder return is up 104.42% and the 5-year total shareholder return is down 5.80%, indicating that recent momentum contrasts with a more mixed longer-term performance.
Spot emerging biotech momentum beyond Sino Biopharmaceutical by scanning a hand picked set of 620 high quality undiscovered gems that sit at the intersection of strong pipelines and underappreciated potential.After a 6.27% single day move to HK$5.59, Sino Biopharmaceutical now trades well below both analyst targets and intrinsic value estimates. Does that gap point to mispricing, or does it represent a fair discount on the recent excitement?
Price-to-Earnings of 35.7x: Is it justified?
Sino Biopharmaceutical trades on a P/E of 35.7x, even though our DCF work flags the stock as trading 65.9% below its estimated fair value of HK$16.41 based on future cash flows.
The P/E ratio compares the current share price with earnings per share. For a research and development focused pharmaceutical group like Sino Biopharmaceutical, a higher P/E often reflects expectations for future profit growth rather than current margins.
Analysts are forecasting earnings to grow around 17% a year, and the company reports high quality earnings. Yet reported profit margins have moved from 12.8% to 7.1%, and return on equity of 14% is flagged as low in this framework. That mix can leave investors asking whether the market is paying a premium for future earnings that are not yet visible in current profitability.
Compared with the Hong Kong Pharmaceuticals industry average P/E of 14.3x and an estimated fair P/E of 23.9x, Sino Biopharmaceutical’s 35.7x multiple is described as expensive versus both peers and the level the market could move towards if sentiment cools.
Explore the SWS fair ratio for Sino Biopharmaceutical
Result: Price-to-Earnings of 35.7x (OVERVALUED)
However, Sino Biopharmaceutical still faces risks if clinical data underwhelms, or if pricing pressure in Mainland China squeezes margins and challenges the current P/E premium.
Find out about the key risks to this Sino Biopharmaceutical narrative.
Another View on Sino Biopharmaceutical’s Valuation
While the P/E of 35.7x suggests Sino Biopharmaceutical is expensive against peers and its own fair ratio, the SWS DCF model points in the opposite direction. On that view, the stock trades around 65.9% below an estimated fair value of HK$16.41. Which signal should carry more weight for you as an investor?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Sino Biopharmaceutical for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 270 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
With sentiment on Sino Biopharmaceutical clearly split between risks and rewards, it makes sense to check the facts yourself and move quickly to form an independent view. To help frame that work, take a closer look at the 3 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Sino Biopharmaceutical?
If Sino Biopharmaceutical has sharpened your focus, now is a good moment to scan fresh opportunities before the next move catches you off guard.
- Target potential mispricing by reviewing a curated set of companies that screen as high quality and possibly underappreciated using the 270 high quality undervalued stocks.
- Prioritise resilience by checking companies with robust finances and clean balance sheets through the list of solid balance sheet and fundamentals (436 results).
- Identify potential income ideas by focusing on companies that combine higher dividend yields with staying power via the 413 dividend fortresses.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com